Scholarworks Repository

Intravitreal bevacizumab for juxtafoveal choroidal neovascularization secondary to multifocal choroiditis

Show simple item record

dc.contributor.author Parodi M.B.
dc.contributor.author Iacono P.
dc.contributor.author Mansour A.
dc.contributor.author Benedetto U.D.
dc.contributor.author Knutsson K.A.
dc.contributor.author Bandello F.
dc.contributor.author Ziemssen F.
dc.contributor.author Ness T.
dc.contributor.author Dodwell D.
dc.contributor.editor
dc.date May-2013
dc.date.accessioned 2017-10-05T15:49:12Z
dc.date.available 2017-10-05T15:49:12Z
dc.date.issued 2013
dc.identifier 10.1097/IAE.0b013e318275397c
dc.identifier.isbn
dc.identifier.issn
dc.identifier.uri http://hdl.handle.net/10938/18713
dc.description.abstract PURPOSE: To assess the effects of intravitreal bevacizumab injections in the treatment of juxtafoveal choroidal neovascularization associated with multifocal choroiditis. METHODS: Prospective interventional case series. Fourteen patients (14 eyes) affected by juxtafoveal choroidal neovascularization secondary to multifocal choroiditis were examined. All patients underwent a complete ophthalmologic examination, including measurement of best-corrected visual acuity using Early Treatment Diabetic Retinopathy Study charts, optical coherence tomography, and fluorescein angiography. The protocol treatment included a first injection, followed by repeated intravitreal bevacizumab injections over a 12-month follow-up period on the basis of optical coherence tomography parameters and angiographic features. RESULTS: Mean best-corrected visual acuity changed from 0.41 logarithm of the minimum angle of resolution (approximately corresponding to 20-51 Snellen equivalent), at baseline, to 0.16 ± 0.13 logarithm of the minimum angle of resolution (approximately corresponding to 20-28 Snellen equivalent), at the 12-month examination (P 0.002). A functional improvement of at least 3 Early Treatment Diabetic Retinopathy Study lines was achieved by 6 eyes (43percent) at the 12-month examination. Mean central macular thickness at baseline was 318 μm, reducing to 239 μm at the 12-month examination (P 0.001). No eye showed choroidal neovascularization extension to the fovea. CONCLUSION: Intravitreal bevacizumab is a beneficial treatment for juxtafoveal choroidal neovascularization associated with multifocal choroiditis. Further studies are warranted to confirm these preliminary results. Copyright © by Ophthalmic communications Society, Inc.
dc.format.extent
dc.format.extent Pages: (953-956)
dc.language English
dc.publisher PHILADELPHIA
dc.relation.ispartof Publication Name: Retina; Publication Year: 2013; Volume: 33; no. 5; Pages: (953-956);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Intravitreal bevacizumab for juxtafoveal choroidal neovascularization secondary to multifocal choroiditis
dc.type Article
dc.contributor.affiliation Parodi, M.B., Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy
dc.contributor.affiliation Iacono, P., Department of Ophthalmology, G. B. Bietti Foundation, IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), 20132 Rome, Italy
dc.contributor.affiliation Mansour, A., Department of Ophthalmology, American University of Beirut, Rafic Hariri University Hospital, Beirut, Lebanon
dc.contributor.affiliation Benedetto, U.D., Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy
dc.contributor.affiliation Knutsson, K.A., Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy
dc.contributor.affiliation Bandello, F., Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy
dc.contributor.affiliation Ziemssen, F., Department of Ophthalmology, University of Tuebingen, Tuebingen, Germany
dc.contributor.affiliation Ness, T., Department of Ophthalmology, University Eye Hospital, Freiburg, Germany
dc.contributor.affiliation Dodwell, D., Department of Ophthalmology, Southern Illinois Univ, School of Medicine, Springfield, IL, United States
dc.contributor.authorAddress Iacono, P.; Department of Ophthalmology, G. B. Bietti Foundation, IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), 20132 Rome, Italy; email: pierluigi.iacono@libero.it
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Ophthalmology;
dc.contributor.authorDepartment Ophthalmology
dc.contributor.authorDivision
dc.contributor.authorEmail pierluigi.iacono@libero.it
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Parodi, MB
dc.contributor.authorInitials Iacono, P
dc.contributor.authorInitials Mansour, A
dc.contributor.authorInitials de Benedetto, U
dc.contributor.authorInitials Knutsson, KA
dc.contributor.authorInitials Bandello, F
dc.contributor.authorInitials Ziemssen, F
dc.contributor.authorInitials Ness, T
dc.contributor.authorInitials Dodwell, D
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Iacono, P (reprint author), Fdn GB Bietti Oftalmol, IRCCS, I-20132 Milan, Italy.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Brown J, 1996, OPHTHALMOLOGY, V103, P1100; CANTRILL HL, 1986, AM J OPHTHALMOL, V101, P170; Deutsch TA, 1985, ANN OPHTHALMOL, V17, P451; DREYER RF, 1984, ARCH OPHTHALMOL-CHIC, V102, P1776; Fine HF, 2009, RETINA-J RET VIT DIS, V29, P8, DOI 10.1097-IAE.0b013e318187aff9; Flaxel CJ, 1998, EYE, V12, P266; Joseph DP, 2003, RETINA-J RET VIT DIS, V23, P463, DOI 10.1097-00006982-200308000-00003; Mansour AM, 2009, AM J OPHTHALMOL, V148, P310, DOI 10.1016-j.ajo.2009.03.023; Michel SS, 2002, OPHTHALMOLOGY, V109, P378, DOI 10.1016-S0161-6420(01)00901-0; MORGAN CM, 1986, OPHTHALMOLOGY, V93, P1138; NOZIK RA, 1973, AM J OPHTHALMOL, V76, P758; Nussenblatt RB, 2007, ACTA OPHTHALMOL SCAN, V85, P230, DOI 10.1111-j.1600-0420.2006.00858.x; Olsen TW, 1996, OPHTHALMOLOGY, V103, P2061; Parodi MB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1100, DOI 10.1001-archophthalmol.2010.205; Parodi MB, 2006, AM J OPHTHALMOL, V141, P23; Parodi MB, 2010, DEV OPHTHALMOL, V46, P84; Parodi MB, 2004, AM J OPHTHALMOL, V138, P263, DOI 10.1016-j.ajo.2004.03.029; Rouvas A, 2011, RETINA-J RET VIT DIS, V31, P871, DOI 10.1097-IAE.0b013e3182003ca8; Shimada H, 2008, JPN J OPHTHALMOL, V52, P282, DOI 10.1007-s10384-008-0566-2; Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P545, DOI 10.1097-00006982-200210000-00003; THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
dc.description.citedCount 2
dc.description.citedTotWOSCount 2
dc.description.citedWOSCount 2
dc.format.extentCount 4
dc.identifier.articleNo
dc.identifier.coden RETID
dc.identifier.pubmedID 23503338
dc.identifier.scopusID 84876982775
dc.identifier.url
dc.publisher.address 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Retin.-J. Retin. Vitr. Dis.
dc.relation.ispartOfIssue 5
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Retina
dc.relation.ispartofPubTitleAbbr Retina
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 33
dc.source.ID WOS:000318011100009
dc.type.publication Journal
dc.subject.otherAuthKeyword
dc.subject.otherChemCAS bevacizumab, 216974-75-3
dc.subject.otherChemCAS Angiogenesis Inhibitors
dc.subject.otherChemCAS Antibodies, Monoclonal, Humanized
dc.subject.otherChemCAS bevacizumab, 2S9ZZM9Q9V
dc.subject.otherIndex bevacizumab
dc.subject.otherIndex adult
dc.subject.otherIndex antiangiogenic therapy
dc.subject.otherIndex article
dc.subject.otherIndex choroiditis
dc.subject.otherIndex clinical article
dc.subject.otherIndex convalescence
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex female
dc.subject.otherIndex fluorescence angiography
dc.subject.otherIndex follow up
dc.subject.otherIndex human
dc.subject.otherIndex male
dc.subject.otherIndex multicenter study
dc.subject.otherIndex multifocal choroiditis
dc.subject.otherIndex optical coherence tomography
dc.subject.otherIndex retina fovea
dc.subject.otherIndex retinal thickness
dc.subject.otherIndex subretinal neovascularization
dc.subject.otherIndex visual acuity
dc.subject.otherIndex Adult
dc.subject.otherIndex Angiogenesis Inhibitors
dc.subject.otherIndex Antibodies, Monoclonal, Humanized
dc.subject.otherIndex Choroidal Neovascularization
dc.subject.otherIndex Choroiditis
dc.subject.otherIndex Female
dc.subject.otherIndex Humans
dc.subject.otherIndex Intravitreal Injections
dc.subject.otherIndex Male
dc.subject.otherIndex Middle Aged
dc.subject.otherIndex Prospective Studies
dc.subject.otherIndex Visual Acuity
dc.subject.otherKeywordPlus PUNCTATE INNER CHOROIDOPATHY
dc.subject.otherKeywordPlus PHOTODYNAMIC THERAPY
dc.subject.otherKeywordPlus SUBRETINAL FIBROSIS
dc.subject.otherKeywordPlus PANUVEITIS
dc.subject.otherWOS Ophthalmology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search Scholarworks


Browse

My Account